The Veeva-Salesforce breakup is one of the most consequential platform shifts in life sciences technology. After building its entire CRM on the Salesforce platform for over a decade, Veeva is migrating to its own Vault platform by 2030. Meanwhile, Salesforce launched Life Sciences Cloud to recapture the market Veeva dominated. For commercial operations teams choosing between them, the decision has never been more complex.
The Breakup Context
Veeva built a $2.4B business on top of Salesforce's platform, paying Salesforce roughly 15% of CRM revenue as a platform fee. In 2022, Veeva announced it would migrate off Salesforce to its own Vault platform. Salesforce responded by launching Life Sciences Cloud and partnering with IQVIA. This isn't just a vendor switch — it's a platform war with your data in the middle.
Data Model Comparison
Veeva CRM (Vault-based): Purpose-built for life sciences from the ground up. The data model natively understands HCPs, HCOs, therapeutic areas, formularies, samples, and compliance requirements. Territory management, call planning, and medical affairs workflows are first-class objects, not customizations. Veeva Network provides master data management for HCP/HCO data with real-time NPI validation.
Salesforce Health Cloud: Built on the Salesforce platform with industry-specific data models layered on top. The Health Cloud data model covers patients, care plans, and clinical data well but requires significant configuration for commercial pharma use cases. Life Sciences Cloud adds pharma-specific objects, but it's still catching up to Veeva's 12 years of domain refinement.
Compliance and Validation
Veeva: GxP-validated infrastructure with 21 CFR Part 11 compliance built in. Veeva Vault has a proven track record with FDA-regulated processes. Sample management, adverse event reporting, and off-label communication guardrails are native features. For regulated content (like CLM presentations), Veeva PromoMats provides end-to-end compliance.
Salesforce: Shield provides encryption and audit trail capabilities, but GxP validation is the customer's responsibility. Salesforce partners (like Veeva competitor Medidata) offer validated solutions on the platform, but the base platform isn't pre-validated for FDA-regulated workflows. This means higher implementation cost for compliance-heavy use cases.
AI Capabilities
Veeva: CRM Bot (now Vault CRM AI) offers next-best-action suggestions, call planning optimization, and content recommendations. Veeva's AI advantage is training on 15+ years of life sciences-specific interaction data. The models understand pharma sales cycles, formulary dynamics, and HCP engagement patterns.
Salesforce: Einstein GPT and Agentforce bring powerful general-purpose AI with life sciences customization. Salesforce's advantage is the breadth of its AI platform — Einstein can pull insights from marketing, service, and commerce clouds, not just CRM. Data Cloud unifies customer data across touchpoints for more comprehensive HCP profiles.
Total Cost of Ownership
Veeva: Higher per-seat licensing ($150-300/user/month for full CRM Suite) but lower implementation cost because the system works out of the box for life sciences. Migration from Salesforce-based Veeva to Vault-based Veeva is positioned as a "lift and shift" but realistically involves 6-12 months of work per brand team.
Salesforce: Lower base licensing ($75-150/user/month for Health Cloud) but significantly higher implementation and customization cost to match Veeva's out-of-box life sciences functionality. Ongoing customization maintenance adds 20-30% annually. However, if you're already a Salesforce shop across other departments, the platform consolidation savings can be substantial.
The Decision Framework
Choose Veeva Vault CRM if: you're a mid-to-large pharma company with established field teams, need turnkey compliance, and want minimal configuration. The migration from Salesforce-based Veeva is inevitable — better to plan it now.
Choose Salesforce Health Cloud if: you're a biotech or emerging pharma building commercial operations from scratch, already use Salesforce enterprise-wide, or need deep marketing/service integration beyond CRM. The total platform value may outweigh the domain-specific gap.
Choose neither yet if: you're a pre-commercial biotech with fewer than 50 field reps. Consider lighter solutions (Pitcher, Aktana, even HubSpot with compliance add-ons) until your commercial operations justify enterprise CRM investment.
Frequently Asked Questions
Why is Veeva leaving Salesforce?
Veeva announced in 2022 that it would migrate its CRM from the Salesforce platform to its own Vault platform by 2030. The primary driver is strategic independence — Veeva was paying Salesforce roughly 15% of CRM revenue as platform fees, and Salesforce's decision to launch its own Life Sciences Cloud made them a direct competitor. By moving to Vault, Veeva controls its entire technology stack and eliminates platform dependency risk.
Should I wait for Veeva Vault CRM or switch to Salesforce now?
If you're currently on Veeva CRM (Salesforce-based), Veeva's migration timeline extends to 2030, so there's no immediate urgency. Start planning your migration roadmap now, but don't rush. If you're choosing a new CRM today, evaluate both: Veeva Vault CRM for turnkey life sciences functionality and compliance, or Salesforce Health Cloud if you need broader platform consolidation across your enterprise and are willing to invest in customization.
What's the total cost difference between Veeva and Salesforce for life sciences?
Veeva has higher per-seat licensing ($150-300/user/month) but lower implementation cost because it works out of the box for pharma commercial operations. Salesforce Health Cloud has lower base licensing ($75-150/user/month) but significantly higher implementation and customization costs — typically 2-3x the implementation budget to match Veeva's out-of-box functionality. Over 3 years, total cost of ownership tends to be similar, but Salesforce may be cheaper if you're already a Salesforce enterprise customer.
